Apple Intelligence Cleared for China as Alibaba and Baidu AI Power iPhone Features 
TSMC Q2 Revenue Surges 36% as AI Chip Demand Powers Growth Ahead of Earnings 
Stripe, Advent Offer $53 Billion Deal to Acquire PayPal: Reuters 
Paramount-Warner Bros. Discovery Merger Faces Lawsuit From 12 States 
Nvidia Tightens AI Chip Sales in Asia With Stricter Customer Approval Process 
ASML Raises 2026 Outlook as AI Chip Demand Lifts Q2 Earnings 
Deutsche Bank Fined A$2 Million by ASIC Over OTC Derivatives Reporting Errors 
SEB Q2 Profit Rises on Strong Lending, Record Fee Income, Announces New Share Buyback 
Muji Owner Ryohin Keikaku Stock Soars After Raising Full-Year Earnings Forecast 
Australia Flags Child Safety Gaps at Apple, Meta, Google Over Online Sexual Extortion 
BHP Faces Major Port Hedland Strike as Labor Talks Stall Ahead of Production Report 
SoftBank Corp Partners With Sierra to Expand AI Customer Support Across Japan 
SK Hynix Shares Drop After Strong Nasdaq Debut Despite $26 Billion ADR Listing 
Morgan Stanley Says China’s Reusable Rocket Progress Poses Long-Term Challenge to SpaceX 
Stellantis Q2 Vehicle Shipments Rise 10% as North America Drives Growth 
Arm Stock Falls After HSBC Downgrade, Citing Limited Near-Term AI Upside 
Mastercard Explores Sale of Majority Stake in UK Payments Firm Vocalink: Report 
WuXi AppTec (SS:603259), a leading Chinese pharmaceutical services company, announced plans to raise HK$7.70 billion (US$981 million) through a Hong Kong share placement to accelerate its global expansion and boost production capacity.
The company will issue 73.8 million new H-shares priced at HK$104.27 each, representing a 6.9% discount to its July 30 closing price. The placement accounts for approximately 2.51% of WuXi AppTec’s enlarged share capital and will be allocated to at least six institutional investors, according to the company’s statement.
WuXi AppTec stated that net proceeds of around HK$7.65 billion will be used mainly to fund overseas growth, with 90% earmarked for international expansion and capacity building projects. The remaining funds will be allocated for general corporate purposes.
This capital raising comes as WuXi AppTec continues to strengthen its global footprint in contract research, development, and manufacturing services amid rising demand for pharmaceutical outsourcing. The move aligns with the company’s strategy to enhance international operations and meet growing customer needs in key markets such as the United States and Europe.
The placement underscores investor confidence in WuXi AppTec’s growth prospects despite broader market volatility. By securing substantial funding, the company is positioned to expand its global infrastructure and maintain its competitive edge in the fast-evolving life sciences sector.
